GSK will use promising results from two studies of its experimental chronic hepatitis B therapy to support planned regulatory ...

GSK's experimental drug to treat chronic hepatitis B infection met the main goal in two closely watched studies, the ...

Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive results from two pivotal Phase 3 studies, ...

Hepatitis B is a virus that can damage the liver and lead to lifelong health problems. The hepatitis B vaccine prevents short ...

GSK on Wednesday said its potential chronic hepatitis B treatment had met primary endpoints in two trials that covered 1,800 ...

Investing.com -- GSK plc (LON:GSK) on Wednesday annoucned positive phase III trial results for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B (CHB), meeting primary ...

By broadening definition of success to include sustained low-level HBsAg with suppressed HBV DNA, we can recognize clinically ...

Alaska public health officials continue to recommend the Hepatitis B vaccine for all newborns, citing high rates of chronic ...

AbbVie (NYSE: ABBV) announced today that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir tablets) for the treatment of acute and chronic hepatitis C virus (HCV) infection in adults and ...

A new rapid test for hepatitis C could help identify many more patients who could be cured of the deadly disease, but its use ...

Hepatitis B is a virus that can damage the liver and lead to lifelong health problems. The hepatitis B vaccine prevents short ...